Eric D. Jacobsen

机构：Dana-Farber Cancer Institute · ORCID：0000-0003-3014-0023

发表论文 360 篇 · 总被引 19081 次 · h-index 54

代表论文

• A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma (2024 · Blood Advances · 被引 31)
• Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia (2025 · Blood Advances · 被引 12)
• Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas (2025 · Blood Advances · 被引 7)
• Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO) (2025 · Blood · 被引 4)
• Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial. (2025 · Journal of Clinical Oncology · 被引 4)
• Forecasting optimal treatments in relapsed/refractory mature T‐ and NK ‐cell lymphomas: A global PETAL Consortium study (2025 · British Journal of Haematology · 被引 4)